Amendment: Dupilumab Alleviates Itching in Various Dermatological Conditions: Insights from Clinical Trials on Atopic Dermatitis, Prurigo Nodularis, and Chronic Spontaneous Urticaria - Quiz - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Amendment: Dupilumab Alleviates Itching in Various Dermatological Conditions: Insights from Clinical Trials on Atopic Dermatitis, Prurigo Nodularis, and Chronic Spontaneous Urticaria

  • By

  • Gil Yosipovitch

  • Brian S. Kim

  • John Y. Koo

  • Zhen Chen

  • Simmi Wiggins

  • Joseph Zahn

  • Philip Sugerman

  • El-Bdaoui Haddad

  • Sonya L. Cyr

  • March 18, 2026

Share

Original Source(s)

Amendment: Dupilumab Alleviates Itching in Various Dermatological Conditions: Insights from Clinical Trials on Atopic Dermatitis, Prurigo Nodularis, and Chronic Spontaneous Urticaria

  • by Gil Yosipovitch, Brian S. Kim, John Y. Koo, Zhen Chen, Simmi Wiggins, Joseph Zahn, Philip Sugerman, El-Bdaoui Haddad, Sonya L. Cyr

  • March 18, 2026

Related Content

Three-Year Efficacy and Safety of Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis: A Long-Term Extension (ADjoin)

Efficacy of Upadacitinib in Treating Atopic Dermatitis in Sensitive Regions: Outcomes from a Multicenter Real-World Study on Hand, Head/Neck, and Genital Involvement

Extended Safety and Effectiveness of Tralokinumab in Individuals with Moderate-to-Severe Atopic Dermatitis Over a 6-Year Period: Final Outcomes from the ECZTEND Open-Label Extension Study